BioCentury
ARTICLE | Company News

Xetrios, Kolltan deal

September 22, 2014 7:00 AM UTC

Kolltan acquired Xetrios for an undisclosed amount. Kolltan said it gains IP covering human therapeutics targeting the TAM receptor tyrosine kinase family, including AXL receptor tyrosine kinase (AX...